RAD51D and ovarian cancer: In a sample of 488 women with nonmetastatic breast cancer, 6.1% had a BRCA1/2 mutation, but mutation prevalence decreased with age (12% in women diagnosed at 45 years of age or younger and 3% in women diagnosed at 46 years of age or older).11 Other genes in the homologous recombination pathway, such as RAD51C, RAD51D, BRIP1, PALB2, and BARD1, may also influence breast and ovarian cancer risk and biology.12-14 Patients with an increased likelihood of having inherited a predisposition to breast and ovarian cancer should receive genetic counseling and be offered genetic testing (Table 1).15